Back to Search
Start Over
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
- Source :
-
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2011 May; Vol. 96 (5), pp. 1301-10. Date of Electronic Publication: 2011 Feb 09. - Publication Year :
- 2011
-
Abstract
- Context: We wanted to understand the effects of once-weekly vs. twice-daily glucagon-like peptide-1 receptor agonism for treatment of patients with type 2 diabetes.<br />Objective: The objective of the study was to compare effects of exenatide once weekly (ExQW) and exenatide twice daily (ExBID) on glycemic control, body weight, and safety.<br />Design: This was a 24-wk, randomized, open-label, comparator-controlled study.<br />Setting: The study was conducted at 43 sites in the United States.<br />Patients: The study population was 252 intent-to-treat patients with type 2 diabetes [baseline (mean ± SD): glycosylated hemoglobin (HbA1c) 8.4 ± 1.2%, fasting plasma glucose 171 ± 47 mg/dl, weight 96 ± 20 kg] that were drug naïve (19%) or previously treated with one (47%) or multiple (35%) oral antidiabetic medications.<br />Interventions: Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk.<br />Main Outcome Measure: The change in HbA1c from baseline to wk 24 was measured.<br />Results: At 24 wk, ExQW produced significantly greater changes from baseline (least squares mean ± SE) vs. ExBID in HbA1c (-1.6 ± 0.1% vs. -0.9 ± 0.1%; P < 0.0001) and fasting plasma glucose (-35 ± 5 mg/dl vs. -12 ± 5 mg/dl; P = 0.0008). Similar reductions in mean body weight from baseline to wk 24 were observed in both groups (-2.3 ± 0.4 kg and -1.4 ± 0.4 kg). Both treatments were generally well tolerated. Transient and predominantly mild to moderate nausea, the most frequent adverse event, was less common with ExQW (14%) than with ExBID (35%). Injection-site reactions were infrequent, but more common with ExQW. No major hypoglycemia occurred.<br />Conclusions: Continuous glucagon-like peptide-1 receptor agonism with ExQW resulted in superior glycemic control, with less nausea, compared with ExBID in patients with type 2 diabetes. Both groups lost weight.
- Subjects :
- Adolescent
Adult
Aged
Blood Pressure physiology
Body Weight physiology
Chromatography, High Pressure Liquid
Combined Modality Therapy
Delayed-Action Preparations
Diabetes Mellitus, Type 2 diet therapy
Drug Therapy, Combination
Enzyme-Linked Immunosorbent Assay
Exenatide
Exercise Therapy
Female
Glycated Hemoglobin metabolism
Humans
Hypoglycemic Agents adverse effects
Male
Middle Aged
Peptides adverse effects
Risk Factors
Venoms adverse effects
Weight Loss drug effects
Young Adult
Blood Glucose metabolism
Diabetes Mellitus, Type 2 blood
Diabetes Mellitus, Type 2 drug therapy
Hypoglycemic Agents administration & dosage
Hypoglycemic Agents therapeutic use
Peptides administration & dosage
Peptides therapeutic use
Venoms administration & dosage
Venoms therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1945-7197
- Volume :
- 96
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- The Journal of clinical endocrinology and metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 21307137
- Full Text :
- https://doi.org/10.1210/jc.2010-2081